Insight Briefs18 November 2025 The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing... Learn more
Insight Briefs17 November 2025 The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More CNS trials fail not from technology limitations but organizational factors. Research reveals 55% of sites lack adequate eCOA... Learn more
Insight Briefs17 November 2025 Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays, staff turnover, and patient acuity... Learn more
Insight Briefs30 October 2025 Implications of Assessing Overall Survival in Oncology Studies The FDA’s August 2025 draft guidance reshapes oncology clinical trials by requiring pre-specified overall survival (OS) analysis in... Learn more
Insight Briefs27 October 2025 The Patient Experience Paradox: eCOA Strategy Overhaul Discover how the EMA’s new Patient Experience Data (PED) guidance and the EU HTA Regulation are reshaping evidence... Learn more
Blog23 September 2025 On-site ePRO in Action: A Recap of Castor’s Product Spotlight Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site... Learn more
Demos9 September 2025 On-site ePRO Castor’s On-site ePRO ensures higher flexibility for both study designers and participants, by maximizing opportunities for data capture. Learn more
Factsheets9 September 2025 Castor On-site ePRO Download our On-site ePRO factsheet to view an overview of our services. Learn more
Blog26 August 2025 EQ-5D in European Trials: When Generic QoL Measures Actually Matter Analysis of 735 FDA drug approvals reveals 0% EQ-5D labeling inclusion, while European HTA bodies demonstrate 18% technology... Learn more
Webinar Castor Product Spotlight: New On-site ePRO Watch this on-demand Product Spotlight to see Castor’s On-site ePRO in action. Our experts show how on-site capture... Learn more
Insight Briefs14 August 2025 Navigating the eCOA Vendor Landscape in 2025: What Clinical Teams Really Need to Know The eCOA market reached $2.27 billion in 2025 with 16.1% projected growth, yet vendor selection remains critical for... Learn more
Insight Briefs7 August 2025 Optimizing eCOA in Oncology Trials: Patient-Focused Data Capture for Cancer Research Oncology leads clinical innovation with 7,747 trials registered through 2022, yet only 7% of cancer patients participate. This... Learn more
Blog31 July 2025 ePRO, eCOA 101: Everything You Need to Know About ePRO and eCOA Electronic Clinical Outcome Assessment (ECOA) and electronic Patient Reported Outcomes (ePRO) represent far more than digital surveys in... Learn more
Blog18 July 2025 Why eCOA Still Fails in Clinical Trials: Practical Strategies to Fix Baseline Data Problems Electronic clinical outcome assessments (eCOA) were supposed to solve data quality and amplify the patient voice. Yet missing... Learn more
Blog26 June 2025 How a 3-Person Team Got to Phase 3 — Without the Overhead Gameto proves you don’t need a large CRO or a floor of data managers to run complex global... Learn more
Webinar Broken at Baseline: Why eCOA Fails in the Real World (and Why We Don’t Talk About It) Why are baseline PROs still going uncaptured in 2025? Join Ari Gnanasakthy, Katja Rudell & Derk Arts to... Learn more
Blog28 May 2025 The New Standard in Participant-Centric Trials: What Castor’s 2025 Updates Reveal About the Future of Clinical Research Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows. Learn more
Success Stories19 May 2025 Oncobiomix: Slashing Costs and Elevating Data Quality Discover how Oncobiomix used an integrated platform for eConsent, EDC, and ePRO to save $100K and streamline data... Learn more
